title: Effects of saline or albumin resuscitation on standard coagulation tests.
abstract: OBJECTIVE
  To explore whether fluid resuscitation with normal saline or 4% albumin is associated with differential changes in routine clinical coagulation tests.
  
  
  METHODS
  Substudy from a large double-blind randomised controlled trial, the SAFE (Saline versus Albumin Fluid Evaluation) study.
  
  
  METHODS
  Three general intensive care units.
  
  
  METHODS
  Cohort of 687 critically ill patients.
  
  
  METHODS
  We randomly allocated patients to receive either 4% human albumin or normal saline for fluid resuscitation, and collected demographic and haematological data.
  
  
  RESULTS
  Albumin was administered to 338 patients and saline to 349. At baseline, the two groups had similar mean activated partial thromboplastin time (APTT) of 37.2 s (albumin) v 39.1 s (saline); mean international normalised ratio (INR) of 1.38 v 1.34, and mean platelet count of 244 x 10(9)/L v 249 x 10(9)/L. After randomisation, during the first day of treatment, the APTT in the albumin group was prolonged by a mean of 2.7 s, but shortened slightly by a mean of -0.9 s in the saline group. The INR did not change in either group, while the platelet count decreased transiently in both groups. Using multivariate analysis of covariance to account for baseline coagulation status, albumin fluid resuscitation (P = 0.01) and a greater overall volume of resuscitation (P = 0.03) were independently associated with prolongation of APTT during the first day.
  
  
  CONCLUSIONS
  Administration of albumin or of larger fluid volumes is associated with a prolongation of APTT. In ICU patients, the choice and amount of resuscitation fluid may affect a routinely used coagulation test.
authors.affiliation: Department of Intensive Care, Austin Hospital, Melbourne, VIC. rinaldo.bellomo@austin.org.au
authors.forename: Rinaldo
authors.initials: R
authors.lastname: Bellomo
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Morimatsu
authors.forename: Jeff
authors.initials: J
authors.lastname: Presneill
authors.forename: Craig
authors.initials: C
authors.lastname: French
authors.forename: Louise
authors.initials: L
authors.lastname: Cole
authors.forename: David
authors.initials: D
authors.lastname: Story
authors.forename: Shigehiko
authors.initials: S
authors.lastname: Uchino
authors.forename: Toshio
authors.initials: T
authors.lastname: Naka
authors.forename: Simon
authors.initials: S
authors.lastname: Finfer
authors.forename: D James
authors.initials: DJ
authors.lastname: Cooper
authors.forename: John
authors.initials: J
authors.lastname: Myburgh
mesh_terms: D000368:Aged; D000418:Albumins / Q000009:adverse effects*; D001777:Blood Coagulation / Q000187:drug effects*; D003422:Critical Care; D005260:Female; D005440:Fluid Therapy / Q000009:adverse effects*; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010952:Plasma Substitutes / Q000009:adverse effects*; D010976:Platelet Count; D012965:Sodium Chloride / Q000009:adverse effects*
chemical_list: D000418:Albumins; D010952:Plasma Substitutes; D012965:Sodium Chloride